PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

Pfizer (PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share ...

Oncology’s Contribution To Pfizer’s EPS. We use adjusted net income margin of around 32%, similar to that of Pfizer overall, to arrive at $0.36 contribution to Pfizer’s total earnings.

Pfizer's earnings estimates beat expectations on Wednesday, due to the company's growing oncology business and slower-than-expected sales declines of its Covid-19 antiviral pill Paxlovid.

Pfizer's Vyndaqel heart disease drug - which earned ~$1.13bn revenues in Q1 2024, is also facing expiring patents - in 2025 in the US - as is Xeljanz, a former $2.5bn per annum autoimmune therapy ...

The New York-based drug company (PFE) had net income of $4.465 billion, or 78 cents a share, for the quarter, after a loss of $2.382 billion, or 42 cents a share, in the year-earlier period.

Pfizer’s PFE Biopharmaceuticals Group, which comprises six business units — Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine — is expected to have ...